cannabis sativa extract

Cannabis sativa extract, in the context of research at the Roswell Park Cancer Institute, refers to a botanical preparation primarily containing delta-9-tetrahydrocannabinol (THC) formulated for administration via vaping. This extract is utilized in clinical studies to investigate the pharmacokinetic and pharmacodynamic interactions between vaped THC and nicotine. THC, the primary psychoactive component, functions as a partial agonist at the cannabinoid CB1 and CB2 receptors. CB1 receptors are predominantly located in the central nervous system and mediate the drug's psychoactive effects, while CB2 receptors are mainly found in the immune system. The research aims to characterize the safety and delivery profile of vaped cannabis products compared to traditional smoked cannabis, particularly in the context of poly-substance use involving nicotine and its potential implications for cannabis dependence.

Other names

THCdelta-9-tetrahydrocannabinoldelta9-tetrahydrocannabinoldelta 9-tetrahydrocannabinolvaped THCCannabis sativa Extract